MARKET

IMNM

IMNM

Immunome Inc
NASDAQ
24.68
-0.84
-3.29%
After Hours: 25.60 +0.92 +3.73% 19:21 03/28 EDT
OPEN
25.53
PREV CLOSE
25.52
HIGH
25.75
LOW
24.21
VOLUME
1.26M
TURNOVER
0
52 WEEK HIGH
30.96
52 WEEK LOW
4.440
MARKET CAP
1.37B
P/E (TTM)
-13.6792
1D
5D
1M
3M
1Y
5Y
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
Imm immunome reported results for the fourth quarter of 2023. Immunome reported earnings per share of -15 cents. The company reported revenue of $3.83 million. This was 84.83% better than the analyst estimate of $2.07 million for the quarter.
Investorplace · 8h ago
Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate
Immunome reports quarterly losses of $0.15 per share. The company reported quarterly sales of $3.83 million which beat the analyst consensus estimate of $2.07 million by 84.83%. The company also reported a 76.56 percent increase in sales for the quarter.
Benzinga · 8h ago
TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)
TipRanks · 14h ago
Press Release: Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets. Topline data for Phase 3 RINGSIDE trial of AL102 expected in the first quarter of 2025. The biotechnology company is focused on developing first-in-class targeted cancer therapies. Immunome's preclinical pipeline includes IM-1021 and IM-3050.
Dow Jones · 16h ago
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
Gold surges to $2,225 per ounce intraday, reaching new all-time highs. U.S. Equity indices held steady in final trading day of March. The S&P 500 and the Dow remained unchanged; the Nasdaq 100 eased by 0.2%. Gold mining stocks rallied as the precious metal updated record highs. The fourth-quarter GDP revised upward to 3.4% for the U.s.
Benzinga · 18h ago
Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment
TipRanks · 3d ago
Press Release: Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals, Inc. AL102 is a potential once-daily oral treatment for desmoid tumors. AL 102 is currently being evaluated in the randomized Phase 3 RINGSIDE international trial. Immunome is a biotechnology company focused on developing first-in-class targeted cancer therapies.
Dow Jones · 3d ago
*Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Dow Jones · 3d ago
More
About IMNM
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Webull offers Immunome Inc stock information, including NASDAQ: IMNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNM stock methods without spending real money on the virtual paper trading platform.